DE60203623D1 - Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren - Google Patents

Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren

Info

Publication number
DE60203623D1
DE60203623D1 DE60203623T DE60203623T DE60203623D1 DE 60203623 D1 DE60203623 D1 DE 60203623D1 DE 60203623 T DE60203623 T DE 60203623T DE 60203623 T DE60203623 T DE 60203623T DE 60203623 D1 DE60203623 D1 DE 60203623D1
Authority
DE
Germany
Prior art keywords
derivatives
angina
substituted piperazine
fat oxidation
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60203623T
Other languages
English (en)
Other versions
DE60203623T2 (de
Inventor
Prabha Ibrahim
Kevin Shenk
Elfatih Elzein
Venkata Palle
Jeff Zablocki
Kenneth Rehder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of DE60203623D1 publication Critical patent/DE60203623D1/de
Application granted granted Critical
Publication of DE60203623T2 publication Critical patent/DE60203623T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Pyridine Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Paper (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60203623T 2001-07-19 2002-07-18 Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren Expired - Fee Related DE60203623T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
US306621P 2001-07-19
PCT/US2002/022897 WO2003008411A1 (en) 2001-07-19 2002-07-18 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (2)

Publication Number Publication Date
DE60203623D1 true DE60203623D1 (de) 2005-05-12
DE60203623T2 DE60203623T2 (de) 2006-01-19

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203623T Expired - Fee Related DE60203623T2 (de) 2001-07-19 2002-07-18 Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren

Country Status (22)

Country Link
US (1) US6930111B2 (de)
EP (1) EP1406898B1 (de)
JP (1) JP2004537554A (de)
KR (1) KR100919141B1 (de)
CN (1) CN1533388A (de)
AT (1) ATE292633T1 (de)
AU (1) AU2008202958A1 (de)
CA (1) CA2454059A1 (de)
DE (1) DE60203623T2 (de)
DK (1) DK1406898T3 (de)
ES (1) ES2236557T3 (de)
HK (1) HK1064374A1 (de)
HU (1) HUP0402088A3 (de)
IL (1) IL159897A0 (de)
MX (1) MXPA04000565A (de)
NO (1) NO327635B1 (de)
NZ (1) NZ530705A (de)
PL (1) PL368529A1 (de)
PT (1) PT1406898E (de)
RU (1) RU2300533C2 (de)
WO (1) WO2003008411A1 (de)
ZA (1) ZA200400404B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
KR101030943B1 (ko) * 2002-05-21 2011-04-28 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2006502134A (ja) * 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体において活性を有する化合物
JP2006506340A (ja) * 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
CA2508608A1 (en) * 2002-12-05 2004-06-24 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1806346B1 (de) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation
AU2003303676A1 (en) 2003-01-03 2004-08-10 Gilead Palo Alto, Inc. Substituted heterocyclic compounds
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
JP2007518677A (ja) * 2003-06-23 2007-07-12 シーブイ・セラピューティクス・インコーポレイテッド 脂肪酸酸化インヒビターとしてのピペラジンおよびピペリジンのウレア誘導体
AU2004303882A1 (en) * 2003-12-18 2005-07-07 Gilead Palo Alto, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1699527A1 (de) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. Mit lipoprotein hoher dichte beschichtete medizinprodukte
WO2006029179A2 (en) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP2056844A4 (de) 2006-08-24 2010-11-24 Wockhardt Research Center Neue makrolide und ketolide mit antimikrobieller wirkung
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
DK2356109T3 (en) * 2008-10-10 2017-03-13 Vm Discovery Inc COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
WO2011115150A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO1998021190A1 (en) * 1996-11-14 1998-05-22 American Home Products Corporation Substituted tetrahydro-1,3,5-triazin-2[1h]-thiones as anti-atherosclerotic agents
WO2001019839A1 (en) * 1999-09-13 2001-03-22 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
EP1259493A2 (de) 2000-02-22 2002-11-27 Cv Therapeutics, Inc. Substituierte piperazin-verbindungen
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001239827A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Also Published As

Publication number Publication date
AU2002322527B2 (en) 2008-04-17
RU2300533C2 (ru) 2007-06-10
ZA200400404B (en) 2004-10-14
AU2002322527A2 (en) 2003-03-03
CA2454059A1 (en) 2003-01-30
EP1406898B1 (de) 2005-04-06
NO20040234L (no) 2004-03-18
WO2003008411A1 (en) 2003-01-30
KR100919141B1 (ko) 2009-09-25
NO327635B1 (no) 2009-09-07
HUP0402088A3 (en) 2010-03-29
RU2004104951A (ru) 2005-06-27
ES2236557T3 (es) 2005-07-16
DK1406898T3 (da) 2005-05-30
IL159897A0 (en) 2004-06-20
DE60203623T2 (de) 2006-01-19
JP2004537554A (ja) 2004-12-16
AU2008202958A1 (en) 2008-07-31
EP1406898A1 (de) 2004-04-14
ATE292633T1 (de) 2005-04-15
US6930111B2 (en) 2005-08-16
PL368529A1 (en) 2005-04-04
HUP0402088A2 (hu) 2005-02-28
KR20040029374A (ko) 2004-04-06
MXPA04000565A (es) 2005-06-17
HK1064374A1 (en) 2005-01-28
US20030181352A1 (en) 2003-09-25
CN1533388A (zh) 2004-09-29
PT1406898E (pt) 2005-08-31
NZ530705A (en) 2005-08-26

Similar Documents

Publication Publication Date Title
DE60203623D1 (de) Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
NO20054969L (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
DE69908648D1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
ATE311380T1 (de) Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
DE60334651D1 (de) Nicotinamide und deren Verwendung als P38 Inhibitoren
CU23210A3 (es) NUEVOS COMPUESTOS DE OXABISPIDINE uTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS
ATE493388T1 (de) Acylierte 1,2,3,4-tetrahydronaphthylamine und deren verwendung als pharmazeutika
DE60236322D1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
ATE345792T1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
HK1111683A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1085467A1 (en) Substituted heterocyclic compounds
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
SE0100326D0 (sv) New compounds
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
DE60200135D1 (de) 4-(2-Pyridyl)piperazine als Agonisten des 5HT7 Rezeptors
WO2004067506A3 (en) Substituted heterocyclic compounds
HUP0101584A2 (hu) Benzofuroxán-származékok és alkalmazásuk angina pectoris kezelésére
PT1334094E (pt) Benzo[b]tiofenos e benzo(d)isotiazoles para diminuir o colesterol
SE0003795D0 (sv) Pharmaceutically useful compounds
WO2006029179A3 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2003303098A8 (en) Process for the preparation of 2-aminomethylpyridine derivative
AR024393A1 (es) Nuevos compuestos de bispidina para usar en el tratamiento de las arritmias cardiacas.
AR024578A1 (es) Nuevos compuestos de bispidinas para usar en el tratamiento de las arritmias cardiacas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee